Biomodal stands out as a leader in the life-sciences technology and analytics sector, with its unique duet multiomics solution that allows for more epigenetic information extraction from a single, low input DNA library, without the need for complex bioinformatics or harsh chemical treatment. This single-base-resolution, phased sequencing approach provides a competitive edge by combining genetic and epigenetic information in one workflow, offering deeper biological insight in areas such as cancer, neurodegenerative disease, and ageing. The potential applications of their technology, as emphasized by CEO Peter Fromen, particularly in oncology, liquid biopsy, aging, and neurodegenerative disorders, further solidifies Biomodal's position as an industry frontrunner.